• 1
    Hynes NE,Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5: 341354.
  • 2
    Daw NC,Furman WL,Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005; 23: 61726180.
  • 3
    Freeman BBIII,Daw NC,Geyer JR,Furman WL,Stewart CF. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest. 2006; 24: 310317.
  • 4
    Baselga J,Rischin D,Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with 5 selected solid tumor types. J Clin Oncol. 2002; 20: 42924302.
  • 5
    Ranson M,Hammond LA,Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002; 20: 22402250.
  • 6
    Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 2004; 306: 15061507.
  • 7
    Yarden Y,Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127137.
  • 8
    Bhargava R,Gerald WL,Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005; 18: 10271033.
  • 9
    Hirsch FR,Varella-Garcia M,Bunn PAJr, et al. Epidermal growth factor receptor in nonsmall-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21: 37983807.
  • 10
    Ohgaki H,Dessen P,Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64: 68926899.
  • 11
    Sunpaweravong P,Sunpaweravong S,Puttawibul P, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005; 131: 111119.
  • 12
    Kersemaekers AM,Fleuren GJ,Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999; 5: 577586.
  • 13
    Moscatello DK,Holgado-Madruga M,Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995; 55: 55365539.
  • 14
    Pedersen MW,Meltorn M,Damstrup L,Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 2001; 12: 745760.
  • 15
    Ji H,Zhao X,Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006; 103: 78177822.
  • 16
    Kuan CT,Wikstrand CJ,Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001; 8: 8396.
  • 17
    Mellinghoff IK,Wang MY,Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353: 20122024.
  • 18
    Lynch TJ,Bell DW,Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 21292139.
  • 19
    Paez JG,Janne PA,Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 14971500.
  • 20
    Pao W,Miller V,Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 1330613311.
  • 21
    Cappuzzo F,Hirsch FR,Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643655.
  • 22
    Moroni M,Veronese S,Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005; 6: 279286.
  • 23
    Raymond AK,Ayala AG,Knuutila S. Conventional osteosarcoma. In: FletcherCDM,UnniKK,MertensF, eds.World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002: 264270.
  • 24
    Ries LAG, Melbert D,Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute. Based on November 2007 SEER data submission, posted to the SEER web site, 2008. Available at: Accessed January 2008.
  • 25
    Marina N,Gebhardt M,Teot L,Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422441.
  • 26
    Bacci G,Longhi A,Versari M,Mercuri M,Briccoli A,Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106: 11541161.
  • 27
    Meyers PA,Heller G,Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10: 515.
  • 28
    Meyers PA,Heller G,Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993; 11: 449453.
  • 29
    Mialou V,Philip T,Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome—the French pediatric experience. Cancer. 2005; 104: 11001109.
  • 30
    Rodriguez-Galindo C,Shah N,McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer. 2004; 100: 19281935.
  • 31
    Tabone MD,Kalifa C,Rodary C,Raquin M,Valteau-Couanet D,Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. JClin Oncol. 1994; 12: 26142620.
  • 32
    Bielack SS,Kempf-Bielack B,Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776790.
  • 33
    Ghanem MA,Van Der Kwast TH,Den Hollander JC, et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer. 2001; 92: 31203129.
  • 34
    Ganti R,Skapek SX,Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006; 19: 12131220.
  • 35
    Hughes DP,Thomas DG,Giordano TJ,Baker LH,McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64: 20472053.
  • 36
    Hughes DP,Thomas DG,Giordano TJ,McDonagh KT,Baker LH. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer. 2006; 46: 614623.
  • 37
    Kersting C,Gebert C,Agelopoulos K, et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res. 2007; 13: 29983005.
  • 38
    Wen YH,Koeppen H,Garcia R, et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol. 2007; 38: 11841191.
  • 39
    Bianco R,Shin I,Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003; 22: 28122822.
  • 40
    Ganti R,Skapek SX,Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006; 19: 12131220.
  • 41
    Pallares J,Bussaglia E,Martinez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of 4 commercial antibodies in correlation with molecular abnormalities. Mod Pathol. 2005; 18: 719727.
  • 42
    Matsuzaki H,Dong S,Loi H, et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods. 2004; 1: 109111.
  • 43
    Beroukhim R,Lin M,Park Y, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006; 2: e41.
  • 44
    Zhao X,Li C,Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004; 64: 30603071.
  • 45
    Li C,Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001; 98: 3136.
  • 46
    Parmigiani G,Garrett ES,Irizarry R,Zeger SL. DNA-Chip Analyzer (dChip). The Analysis of Gene Expression Data: Methods and Software. New York, NY: Springer; 2003: 120141.
  • 47
    Bjornsti MA,Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4: 335348.
  • 48
    Fukaya Y,Ishiguro N,Senga T, et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep. 2005; 14: 847852.
  • 49
    She QB,Solit D,Basso A,Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res. 2003; 9: 43404346.
  • 50
    Wan X,Mendoza A,Khanna C,Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005; 65: 24062411.
  • 51
    Inoue R,Matsuki NA,Jing G,Kanematsu T,Abe K,Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol. 2005; 146: 633641.
  • 52
    Wang MY,Lu KV,Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006; 66: 78647869.
  • 53
    Huvos AG,Rosen G,Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 1418.
  • 54
    Rosen G,Marcove RC,Caparros B,Nirenberg A,Kosloff C,Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979; 43: 21632177.
  • 55
    Rosen G,Murphy ML,Huvos AG,Gutierrez M,Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976; 37: 111.